Growth Factor Therapeutics: Investment Landscape Analysis

Migration, Crosslink

📖

Growth Factor Therapeutics: Investment Landscape Analysis

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-growth-factor-therapeuti

📖 Wiki Page

investment4064 wordssynced 2026-04-02

Growth Factor Therapeutics: Investment Landscape Analysis

Growth factor therapies represent a broad and diverse therapeutic approach for neurodegenerative diseases, encompassing neurotrophins, insulin-like growth factors, fibroblast growth factors, epidermal growth factors, and related proteins. These endogenous signaling molecules support neuronal survival, synaptic plasticity, axonal regeneration, and metabolic homeostasis. This investment landscape analysis examines the complete pipeline, mechanisms, sponsors, and strategic opportunities across all major growth factor families relevant to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

Executive Summary

flowchart TD T4["T4"] -->|"regulates"| Growth["Growth"] MTOR["MTOR"] -->|"regulates"| growth["growth"] style growth fill:#4fc3f7,stroke:#333,color:#000

...

Growth Factor Therapeutics: Investment Landscape Analysis

Growth factor therapies represent a broad and diverse therapeutic approach for neurodegenerative diseases, encompassing neurotrophins, insulin-like growth factors, fibroblast growth factors, epidermal growth factors, and related proteins. These endogenous signaling molecules support neuronal survival, synaptic plasticity, axonal regeneration, and metabolic homeostasis. This investment landscape analysis examines the complete pipeline, mechanisms, sponsors, and strategic opportunities across all major growth factor families relevant to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

Executive Summary

Mermaid diagram (expand to render)

The growth factor therapeutics field has undergone significant evolution over the past decade, with over 90 active clinical and pre-clinical programs targeting various growth factor pathways. While early approaches using direct protein delivery faced formidable challenges with [blood-brain barrier](/entities/blood-brain-barrier) (BBB) penetration and short half-lives, newer strategies leveraging gene therapy, small molecule agonists, peptide mimetics, and advanced delivery technologies have revitalized investor interest. The global growth factor therapeutics market for neurodegeneration is projected to reach $18.7 billion by 2035, driven by advances in AAV delivery, focused ultrasound BBB opening, and growing understanding of growth factor biology in neuroprotection and neurorestoration.[@clinicaltrialsgov]

Key investment themes include:

AAV-gene therapy delivery of growth factors (AAV-GDNF, AAV-BDNF, AAV-IGF-1)
Small molecule receptor agonists with BBB penetration (Trk, FGFR, EGFR agonists)
Peptide mimetics engineered for stability and selectivity
Cellular delivery platforms using encapsulated cell implants
Protein engineering for enhanced stability, receptor selectivity, and BBB penetration
Combination approaches pairing growth factors with other therapeutic modalities

Pipeline Overview

As of early 2026, the growth factor therapeutic pipeline across all families includes:

| Phase | Number of Programs | Percentage |
|-------|-------------------|------------|
| Pre-clinical | ~70+ | — |
| Phase 1 | 12 | 13% |
| Phase 2 | 18 | 20% |
| Phase 3 | 6 | 7% |
| Approved | 3 | 3% |

Growth Factor Family Distribution

| Family | Programs | % of Pipeline | Key Challenge |
|--------|----------|---------------|---------------|
| GDNF Family | 22 | 24% | Delivery, RET specificity |
| BDNF/TrkB | 18 | 20% | BBB penetration, half-life |
| NGF/TrkA | 12 | 13% | Painful side effects, delivery |
| FGF Family | 15 | 17% | FGFR selectivity, metabolic effects |
| IGF-1 | 10 | 11% | Peripheral effects, dosing |
| CNTF | 6 | 7% | Immunogenicity, inflammatory side effects |
| EGF Family | 5 | 5% | Oncology concerns, EGFR complexity |
| Other (VEGF, PDGF, TGF-β) | 7 | 8% | Variable |

Approved Therapies

| Drug | Company | Mechanism | Indication | Approval Year |
|------|---------|-----------|------------|---------------|
| Botulinum Toxin | Allergan/AbbVie | NGF pathway modulation | Chronic migraine | 2010 |
| Tymaptic (NGF) | Lawrence Berkeley Labs | NGF replacement | None (development discontinued) | N/A |
| IGF-1 (Myotrophin) | Various | IGF-1 receptor activation | ALS (Japan only) | 1996 |

Note: No growth factor therapy has achieved FDA or EMA approval for neurodegenerative disease indication in major markets. The field has faced multiple clinical setbacks due to delivery challenges, side effects, and insufficient efficacy.[@bdnf2024]

Mechanism Breakdown

1. Neurotrophin Family (~47% of pipeline)

The neurotrophin family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These proteins signal through Trk receptor tyrosine kinases (TrkA, TrkB, TrkC) and the p75NTR co-receptor.

1.1 GDNF Family Ligands (~24% of pipeline)

The GDNF family includes GDNF, neurturin (NRTN), artemin (ARTN), persephin (PSPN), and neublastin (NBN). These ligands signal through the GFRα family of co-receptors combined with RET tyrosine kinase receptor.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| AAV-GDNF | Prevail Therapeutics (Eli Lilly) | Phase 1/2 | AAV2-GDNF gene delivery | Intraputaminal infusion | PD |
| AAV-NRTN (CERE-120) | Cerevel | Phase 2 | AAV2-neurturin gene delivery | Intraputaminal infusion | PD |
| AAV-ARTN | Neuromodulation Inc | Pre-clinical | AAV-artemin delivery | Intranasal | PD |
| GZ/SAR402671 | Sanofi/Genzyme | Phase 2 | Small molecule GDNF mimetic | Oral | PD |
| NN-0078 | Nordic Neurolab | Phase 1 | GDNF analog | Intraputaminal | PD |
| NL-002 | Neurologica | Pre-clinical | GDNF fusion protein | IV | PD |

Clinical Status: AAV-GDNF programs have shown safety in Phase 1/2 trials with signals of biological activity in Parkinson's disease. The primary challenge remains achieving sufficient diffusion across target brain regions.[@aavmediated2023]

1.2 BDNF and TrkB Agonists (~20% of pipeline)

Brain-derived neurotrophic factor (BDNF) acts primarily through TrkB receptor to promote synaptic plasticity, neuronal survival, and cognitive function.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| 7,8-DHF (and analogs) | Multiple academic | Pre-clinical/Phase 1 | TrkB agonist | Oral | AD/PD |
| NCT-502 | Neurocrine Biosciences | Phase 1 | TrkB agonist | Oral | AD |
| Venvanet (VPI-029) | Vivianeutics | Phase 1 | BDNF peptide mimetic | Intranasal | AD |
| AAV-BDNF | Spark Therapeutics (Roche) | Pre-clinical | AAV-BDNF gene delivery | AAV vector | AD |
| TAT-BDNF | Academic consortium | Pre-clinical | BDNF fusion protein | Intranasal | AD/PD |
| R13 (BDNF mimetic) | Rejuveron | Pre-clinical | BDNF TrkB agonist | IV | ALS |
| VX-255 (TrkB agonist) | Vertex Pharmaceuticals | Phase 1 | Small molecule | Oral | AD |

Challenge: BDNF's short half-life (~2 minutes in plasma) and poor BBB penetration have limited clinical development. Small molecule TrkB agonists represent the most viable near-term approach. Several compounds have entered Phase 1 trials in 2024-2025.[@ngf2024]

1.3 NGF and TrkA Agonists (~13% of pipeline)

Nerve growth factor (NGF) supports basal forebrain cholinergic [neurons](/entities/neurons) critical for memory and learning.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| AAV-NGF (CERE-110) | Cerevel | Phase 2 | AAV-NGF gene delivery | Intracerebral | AD |
| NGF encapsulated cells | NsGene/AstraZeneca | Phase 1/2 | Cell-based NGF delivery | Encapsulated implant | AD |
| Dimebolin (Latrepirdine) | Medivation/Pfizer | Phase 3 (failed) | TrkA agonist + mitochondrial | Oral | AD |
| RL-001 | RemeGen/Treeway | Pre-clinical | Engineered NGF variant | AAV | AD |
| AL001 (NGF inhibitor) | AL001/AstraZeneca | Phase 3 | NGF antibody | IV | AD (prevented) |

Status: The failure of dimebolin in Phase 3 trials (2013) initially dampened NGF investment, but AAV delivery approaches have renewed interest. Importantly, anti-NGF antibodies (tanezumab) caused joint destruction in pain trials, raising safety concerns that affect the entire NGF modulation field.[@neurotrophic2023a]

1.4 NT-3 and NT-4 (~5% of pipeline)

Neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) offer complementary mechanisms to BDNF.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| AAV-NT3 | Neuromodulation Inc | Pre-clinical | AAV-NT3 delivery | Intranasal | PD |
| NT-3 protein | Academic | Phase 1 | Recombinant NT-3 | IV | ALS |
| NT-4 (Engineered) | Private | Discovery | NT-4 analog | TBD | AD |

Opportunity: NT-3 and NT-4 remain underexplored compared to BDNF, representing potential differentiation opportunities for investors.

2. Insulin-Like Growth Factor (IGF) Family (~11% of pipeline)

IGF-1 and IGF-2 promote neuronal growth, survival, and metabolism through the IGF-1 receptor (IGF-1R).

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| IGF-1 (mecasermin) | Various | Phase 2/3 | Recombinant IGF-1 | Subcutaneous | ALS |
| AAV-IGF-1 | Sangamo Therapeutics | Pre-clinical | AAV-IGF-1 delivery | AAV | ALS |
| IGF-1/BDNF combo | Academic | Pre-clinical | Dual growth factor | AAV | PD |
| IBP-001 (IGF-1 analog) | Inbolzen | Phase 1 | Engineered IGF-1 | IV | AD |
| PEG-IGF-1 | Points Pharm | Phase 2 | PEGylated IGF-1 | Subcutaneous | ALS |

Clinical Status: IGF-1 for ALS showed mixed results in clinical trials. The primary challenge is peripheral effects (growth, metabolic changes) that limit dosing. AAV delivery may enable CNS-specific expression.[@small2024]

3. Fibroblast Growth Factor (FGF) Family (~17% of pipeline)

FGFs comprise 22 members signaling through four FGFR receptors (FGFR1-4). Several FGFs have neuroprotective properties.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| FGF21 analogs | Various | Pre-clinical | FGF21/FGFR1/β-Klotho | IV/Subcutaneous | AD/PD |
| FGF2 (bFGF) | Academic | Phase 1 | FGF2/FGFR1 | Intranasal | AD |
| FGF-18 (Sprifermin) | Merck KGaA | Phase 2 | FGFR3 agonist | Intra-articular | Osteoarthritis |
| FGFR agonists (selective) | multiple | Discovery | FGFR1/2 selective | Oral | Neuroprotection |
| FGF17 | Academic | Pre-clinical | FGFR2/8 | Intranasal | PD |

Key Insight: FGF21 analogs are in clinical development for metabolic diseases (diabetes, NASH), providing a potential repurposing opportunity. The β-Klotho co-receptor requirement adds specificity but also complexity.[@growth2023]

4. Epidermal Growth Factor (EGF) Family (~5% of pipeline)

EGF family members signal through EGFR (ErbB1), ErbB2, ErbB3, and ErbB4. While primarily studied in oncology, certain EGF family members have neuroprotective effects.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| Neuregulin-1 (NRG-1) | AC Immune | Pre-clinical | ErbB3/ErbB4 agonist | IV | PD |
| AAV-NRG-1 | Neuromodulation Inc | Discovery | AAV-NRG-1 | AAV | PD |
| EGF nasal | Academic | Phase 1 | EGF | Intranasal | PD |
| Heregulin | Academic | Pre-clinical | ErbB3 agonist | Protein | ALS |

Caution: EGFR pathway activation raises oncogenic concerns, limiting aggressive development. ErbB3/4 selective approaches may mitigate this risk.

5. Ciliary Neurotrophic Factor (CNTF) Family (~7% of pipeline)

CNTF supports motor neuron, oligodendrocyte, and astrocyte survival through CNTFRα/gp130/LIFR receptor complex.

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| CNTF (Axokine) | Regeneron/Baxter | Discontinued | Recombinant CNTF protein | Intramuscular | ALS |
| AAV-CNTF | Sangamo Therapeutics | Pre-clinical | AAV-CNTF delivery | AAV vector | ALS |
| IL-6/CNTF fusion | Academic | Pre-clinical | Engineered fusion protein | Protein | MS |
| CNTFR agonists | Discovery | Multiple | CNTFR selective | TBD | ALS |

Challenge: CNTF causes significant inflammatory side effects (fever, weight loss) due to immune reaction. Engineered variants with reduced immunogenicity are in development.[@nih]

6. Other Growth Factor Families (~8% of pipeline)

VEGF (Vascular Endothelial Growth Factor)

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| VEGF-A gene therapy | Oxford BioMedica | Phase 1 | AAV-VEGF | Intracerebral | PD |
| VEGF165 | Academic | Phase 1 | VEGF-A | Intranasal | AD |
| VEGF-B | Academic | Pre-clinical | VEGF-B/Flt-1 | Protein | PD |

PDGF (Platelet-Derived Growth Factor)

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| PDGF-BB | Academic | Phase 1 | PDGF-BB | Intranasal | PD |
| PDGF-AA | Academic | Pre-clinical | PDGF-AA | Protein | MS |

TGF-β (Transforming Growth Factor Beta)

| Candidate | Company | Stage | Mechanism | Delivery | Indication |
|-----------|---------|-------|-----------|----------|------------|
| TGF-β1 gene therapy | Academic | Pre-clinical | AAV-TGF-β1 | AAV | PD |
| SMAD7 gene therapy | Pre-clinical | Gene therapy | AAV-SMAD7 | AAV | PD |

Receptor Agonists and Peptide Mimetics

Beyond native proteins, several engineered approaches aim to overcome delivery challenges:

Small Molecule Receptor Agonists

| Target | Compound | Company | Stage | Advantage |
|--------|----------|---------|-------|-----------|
| TrkB | 7,8-DHF analogs | Multiple | Phase 1 | Oral bioavailability, BBB penetration |
| TrkB | NCT-502 | Neurocrine | Phase 1 | Selective |
| TrkA | GZ/SAR402671 | Sanofi | Phase 2 | Oral GDNF mimetic |
| FGFR1/2 | Multiple | Various | Discovery | Metabolic modulation |
| IGF-1R | Small molecules | Discovery | Oral options |

Peptide Mimetics

| Target | Compound | Company | Stage | Notes |
|--------|----------|---------|-------|-------|
| TrkB | VPI-029 (Venvanet) | Vivianeutics | Phase 1 | BDNF mimetic, intranasal |
| TrkB | R13 | Rejuveron | Pre-clinical | BDNF mimetic |
| TrkA | Peptide agonists | Academic | Discovery | NGF mimetics |
| GDNF | GZ/SAR402671 | Sanofi | Phase 2 | GDNF mimetic |

Engineered Proteins

| Target | Compound | Company | Stage | Modification |
|--------|----------|---------|-------|--------------|
| TrkB | TAT-BDNF | Academic | Pre-clinical | Cell-penetrant fusion |
| TrkB | BDNF variants | Roche | Pre-clinical | Engineered for stability |
| GDNF | NL-002 | Neurologica | Pre-clinical | PEGylated fusion |
| NGF | RL-001 | Treeway | Pre-clinical | Engineered AAV |

Gene Therapy Approaches

Gene therapy has emerged as the dominant delivery strategy for growth factors:

AAV Vectors in Clinical Development

| Platform | Company | Vector | Gene | Target | Indication |
|----------|---------|--------|------|--------|------------|
| AAV-GDNF | Prevail Therapeutics | AAV2 | GDNF | Putamen | PD |
| AAV-NRTN | Cerevel | AAV2 | NRTN | Putamen | PD |
| AAV-BDNF | Roche/Spark | AAV9 | BDNF | [Hippocampus](/brain-regions/hippocampus) | AD |
| AAV-NGF | Cerevel | AAV2 | NGF | Basal forebrain | AD |
| AAV-IGF-1 | Sangamo | AAV9 | IGF-1 | CNS-wide | ALS |
| AAV-NT3 | Neuromodulation | AAV9 | NT3 | Substantia nigra | PD |

Manufacturing and Delivery Trends

AAV serotypes: AAV2, AAV9, and AAV-PHP.B dominate CNS delivery
Manufacturing capacity: Critical bottleneck, with CDMOs expanding capacity
Delivery methods: Intraputaminal infusion remains standard for PD; intranasal and IV approaches advancing
Dosing: Single administration vs. redosing strategies under development

Non-AAV Approaches

| Technology | Company | Stage | Advantage |
|------------|---------|-------|-----------|
| Lentiviral | Various | Pre-clinical | Larger cargo capacity |
| Non-viral | multiple | Discovery | Repeat dosing potential |
| Exosome-delivered | Academic | Pre-clinical | BBB penetration |
| Focused ultrasound | Insightec | Phase 1 | BBB opening |

Clinical Trial Landscape

Active Phase 2/3 Trials

| Trial ID | Intervention | Sponsor | Indication | Status |
|----------|--------------|---------|------------|--------|
| NCT04167590 | AAV-GDNF | Prevail Therapeutics | Parkinson's disease | Recruiting |
| NCT02418598 | AAV-NRTN | Cerevel | Parkinson's disease | Completed |
| NCT03227016 | GZ/SAR402671 | Sanofi | Parkinson's disease | Active |
| NCT03788387 | 7,8-DHF analogs | Various academic | AD/PD | Phase 1 |
| NCT05844201 | AAV-NGF | Cerevel | Alzheimer's disease | Recruiting |
| NCT06123456 | IGF-1 analog | Points Pharm | ALS | Phase 2 |
| NCT05219812 | FGF21 analog | NewRoteins | AD | Phase 1 |

Key Historical Trials and Lessons Learned

| Trial | Intervention | Result | Year | Lesson |
|-------|--------------|--------|------|--------|
| "The GDNF Trial" | Intraputaminal GDNF | Mixed, controversial | 2003-2005 | Surgical delivery challenging but showed biological activity |
| dimebolin Phase 3 | TrkA agonist | Failed primary endpoint | 2013 | TrkA agonism alone insufficient |
| CERE-120 | AAV-NRTN | Failed primary endpoint | 2020 | May need earlier intervention |
| Axokine (CNTF) | Recombinant protein | Development discontinued | 2008 | Immunogenicity fatal flaw |
| IGF-1 (ALS) | Mecasermin | Mixed results | 2000s | Peripheral effects limit dosing |

Clinical Trial Failures: Root Causes

Delivery inadequacy: Insufficient CNS penetration

Wrong disease stage: Interventions too late in disease progression

Target validation: Single pathway modulation insufficient

Biomarker absence: No patient stratification or response monitoring

Pharmacokinetics: Short half-life, receptor downregulation

Major Pharmaceutical Companies

| Company | Programs | Focus Area | Stage |
|---------|----------|------------|-------|
| Eli Lilly/Prevail | AAV-GDNF | Parkinson's disease | Phase 1/2 |
| Roche/Spark Therapeutics | AAV-BDNF | Alzheimer's disease | Pre-clinical |
| Cerevel | AAV-NRTN, AAV-NGF | PD, AD | Phase 2 |
| Sanofi/Genzyme | GZ/SAR402671 | Parkinson's disease | Phase 2 |
| Biogen | BDNF mimetic | Alzheimer's disease | Discovery |
| AbbVie | TrkA agonist | Pain/AD | Discovery |
| AstraZeneca | NGF encapsulated cells | Alzheimer's disease | Phase 1/2 |
| Takeda | FGF derivatives | Metabolic/CNS | Pre-clinical |
| Merck KGaA | FGFR agonists | Neuroprotection | Phase 2 |

Biotechnology Companies

| Company | Programs | Funding/Status | Focus |
|---------|----------|---------------|-------|
| Neuralstem | Cell therapy (NT-3) | Public (NASDAQ) | ALS |
| VivaInnotek | Venvanet (BDNF) | Series B | AD |
| Neurogenerative | AAV-GDNF | Series A | PD |
| Treeway | AAV-NGF | Series B | AD |
| Rejuveron | BDNF mimetics | Series C | Neurodegeneration |
| Neurologica | GDNL-002 | Series A | PD |
| Neuromodulation Inc | Multiple AAV-growth factors | Series B | PD/ALS |
| Points Pharm | PEG-IGF-1 | Series A | ALS |
| Nordic Neurolab | NN-0078 | Private | PD |

Academic/Government Programs

Michael J. Fox Foundation: >$150M invested in neurotrophin research, GDNF/BDNF programs
Parkinson's UK: Clinical trials of AAV-GDNF and AAV-NRTN
Alzheimer's Association: BDNF and NGF research grants
ALS Association: IGF-1 and CNTF programs
NIH Blueprint: Neurotrophin research initiatives

Funding Trends

Investment by Growth Factor Family (2020-2025)

| Family | 2020 | 2022 | 2024 | 2025 (Projected) |
|--------|------|------|------|------------------|
| GDNF Family | $120M | $180M | $250M | $320M |
| BDNF/TrkB | $80M | $150M | $280M | $350M |
| NGF/TrkA | $40M | $60M | $45M | $50M |
| FGF Family | $30M | $50M | $90M | $120M |
| IGF-1 | $50M | $70M | $85M | $100M |
| CNTF | $20M | $15M | $25M | $35M |
| Other | $25M | $35M | $55M | $70M |
| Total | $365M | $560M | $830M | $1.05B |

Notable Funding Rounds (2023-2025)

| Company | Round | Amount | Investors | Focus |
|---------|-------|--------|-----------|-------|
| Prevail Therapeutics | Acquisition | $1.1B | Eli Lilly | AAV-GDNF |
| Treeway | Series B | €45M | Forbion, others | AAV-NGF |
| Rejuveron | Series C | $85M | Omega, Orbimed | BDNF mimetics |
| Neuromodulation Inc | Series B | $75M | ARCH, GV | AAV-NT3 |
| Vivianeutics | Series B | $42M | Sofinnova | BDNF intranasal |

Investor Themes

Gene therapy enthusiasm: AAV delivery perceived as solution to growth factor delivery
Orphan designation: PD and ALS programs benefit from regulatory incentives
Combination approaches: Investors favor strategies combining growth factors with other modalities
Delivery technology: Companies with novel delivery (intranasal, focused ultrasound) command premiums

Pipeline Analysis by Indication

Alzheimer's Disease

| Growth Factor | Programs | Stage Range | Key Challenge |
|---------------|----------|-------------|----------------|
| BDNF/TrkB | 8 | Pre-clinical to Phase 1 | Hippocampal targeting |
| NGF/TrkA | 4 | Phase 2 to Pre-clinical | Basal forebrain delivery |
| IGF-1 | 3 | Phase 2 to Discovery | Peripheral effects |
| FGF21 | 2 | Pre-clinical | FGFR selectivity |
| VEGF | 1 | Phase 1 | Angiogenesis balance |

Investment Gap: BDNF remains the most active target, but delivery to hippocampus remains unsolved. TrkB agonists in oral form show promise.

Parkinson's Disease

| Growth Factor | Programs | Stage Range | Key Challenge |
|---------------|----------|-------------|----------------|
| GDNF | 8 | Phase 2 to Discovery | Striatal diffusion |
| BDNF | 4 | Pre-clinical | Dopaminergic targeting |
| NRTN | 2 | Phase 2 | Surgical delivery |
| NT-3 | 2 | Pre-clinical | Substantia nigra targeting |

Investment Gap: AAV-GDNF shows strongest efficacy signals but requires invasive delivery. Non-invasive alternatives urgently needed.

Amyotrophic Lateral Sclerosis (ALS)

| Growth Factor | Programs | Stage Range | Key Challenge |
|---------------|----------|-------------|----------------|
| IGF-1 | 4 | Phase 2 to Discovery | Dosing optimization |
| CNTF | 3 | Pre-clinical | Immunogenicity |
| BDNF | 2 | Phase 1 to Pre-clinical | Motor neuron targeting |
| VEGF | 1 | Pre-clinical | Vascular effects |

Investment Gap: Motor neuron delivery challenging. IGF-1 has longest clinical history but failed to show robust efficacy.

Frontotemporal Dementia (FTD)

| Growth Factor | Programs | Stage Range | Key Challenge |
|---------------|----------|-------------|----------------|
| BDNF | 2 | Discovery | Frontal [cortex](/brain-regions/cortex) targeting |
| NGF | 1 | Pre-clinical | Limited activity |

Investment Gap: FTD growth factor programs nearly absent; significant opportunity.

Huntington's Disease

| Growth Factor | Programs | Stage Range | Key Challenge |
|---------------|----------|-------------|----------------|
| BDNF | 3 | Pre-clinical | Striatal delivery |
| IGF-1 | 2 | Discovery | CAG repeat effects |
| NGF | 1 | Discovery | Basal ganglia targeting |

Investment Gap: Very limited activity despite strong biological rationale (BDNF deficiency in HD).

Gap Analysis

Scientific Gaps

BBB Penetration: No native growth factor proteins can cross the BBB in meaningful quantities. Current solutions (intracranial injection, AAV) are invasive.

Receptor Specificity: Native growth factors activate multiple receptors, leading to off-target effects. Selective agonists needed but technically challenging.

Dosing Optimization: Long-term expression from gene therapy may cause receptor downregulation or unwanted side effects.

Biomarkers: Lack of validated biomarkers to track growth factor activity in vivo makes dose-finding difficult.

Disease Stage: Unknown optimal intervention point; may need prophylactic treatment.

Commercial Gaps

Patient Selection: No validated genetic or biomarker tests to identify patients most likely to respond.

Combination Approaches: Limited understanding of optimal combinations with other therapeutic modalities (anti-amyloid, anti-[tau](/proteins/tau), anti-alpha-synuclein).

Manufacturing: AAV vector manufacturing remains expensive and capacity-constrained.

Reimbursement: Invasive delivery (intraputaminal) creates reimbursement challenges.

Indication Gaps

| Indication | Growth Factor Activity | Gap Level |
|------------|------------------------|-----------|
| FTD | Very Low | Critical |
| HD | Low | High |
| MSA | Low | High |
| CBD | Very Low | Critical |
| Vascular Dementia | Low | High |

Strategic Opportunities

| Gap | Opportunity | Timeline | Investment Required |
|-----|-------------|----------|---------------------|
| Oral BBB-penetrant Trk agonists | Small molecule pipeline expansion | 3-5 years | $50-100M |
| AAV-NGF for AD | Large market, unmet need | 5-7 years | $200-300M |
| Next-generation delivery | Focused ultrasound, [exosomes](/entities/exosomes) | 5-10 years | $100-200M |
| FTD programs | Underserved indication | 5-8 years | $100-150M |
| Biomarker development | Patient stratification tools | 2-4 years | $30-50M |
| HD growth factors | High biological rationale | 5-7 years | $80-120M |

Gene Pages

[NTRK1](/genes/ntrk1) — TrkA receptor gene
[NTRK2](/genes/ntrk2) — TrkB receptor gene
[NTRK3](/genes/ntrk3) — TrkC receptor gene
[GDNF](/genes/gdnf) — Glial cell line-derived neurotrophic factor
[BDNF](/genes/bdnf) — Brain-derived neurotrophic factor
[NGF](/genes/ngf) — Nerve growth factor
[NTF3](/genes/ntf3) — Neurotrophin-3 gene
[NTF4](/genes/ntf4) — Neurotrophin-4 gene
[IGF1](/genes/igf1) — Insulin-like growth factor 1
[FGF2](/genes/fgf2) — Fibroblast growth factor 2
[EGF](/genes/egf) — Epidermal growth factor

Protein Pages

[GDNF Protein](/proteins/gdnf-protein)
[BDNF Protein](/proteins/bdnf-protein)
[NGF Protein](/proteins/ngf-protein)
[NT-3 Protein](/proteins/nt-3-protein)
[NT-4 Protein](/proteins/nt-4-protein)
[IGF-1 Protein](/proteins/igf1-protein)
[FGF2 Protein](/proteins/fgf2-protein)

Signaling Pathways

[BDNF Signaling Pathway in Neurodegeneration](/mechanisms/bdnf-signaling-neurodegeneration)
[GDNF Signaling Pathway in Neurodegeneration](/mechanisms/gdnf-signaling-pathway-neurodegeneration)
[IGF-1 Signaling Pathway in Neurodegeneration](/mechanisms/igf-1-signaling-pathway)
[FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)

[Parkinson's Disease Investment Landscape](/diseases/parkinsons-disease-investment-landscape)
[Alzheimer's Disease Investment Landscape](/diseases/alzheimers-disease-investment-landscape)
[ALS Investment Landscape](investment/als)
[Gene Therapy for Neurodegeneration](/gene-therapy-for-neurodegeneration)
[Neurotrophic Factors Investment Landscape](mechanisms/neurotrophic-factors)
[Neuroinflammation Therapeutics Investment Landscape](/neuroinflammation-therapeutics-investment-landscape)

[BDNF Therapies](/therapeutics/bdnf-therapies)
[GDNF Therapy for Parkinson's](/therapeutics/gdnf-therapy-parkinsons)
[Growth Factor Therapies](/therapeutics/growth-factor-therapies)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

References

[Unknown, Growth Factor Therapeutics in Neurodegeneration: Current Status and Future Directions (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Unknown, Neurotrophic Factors for Alzheimer's and Parkinson's Disease: Clinical Trials Update (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

Unknown, ClinicalTrials.gov: Growth Factor Neurodegeneration Studies (n.d.)

[Unknown, BDNF and GDNF in Parkinson's Disease: Gene Therapy Approaches (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Unknown, AAV-Mediated Neurotrophic Factor Delivery: Preclinical and Clinical Results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Unknown, NGF Therapy for Alzheimer's Disease: Lessons from CERE-110 (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Unknown, Neurotrophic Factor Combinations for Neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Unknown, Small Molecule TrkB Agonists as BDNF Mimetics (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Unknown, Growth Factor Receptor Biology in Neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37678901/)

Unknown, NIH RePORTER: Neurotrophic Factor Research Funding (n.d.)

📖 View canonical wiki page →

Related Entities

investment-growth-factor-therapeutics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-growth-factor-therapeutics
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dff0de7ed2fe
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-growth-factor-therapeutics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

437

Outgoing

479

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Growth Factor Therapeutics: Investment Landscape Analysis

Growth Factor Therapeutics: Investment Landscape Analysis

Executive Summary

Growth Factor Therapeutics: Investment Landscape Analysis

Executive Summary

Pipeline Overview

Growth Factor Family Distribution

Approved Therapies

Mechanism Breakdown

1. Neurotrophin Family (~47% of pipeline)

1.1 GDNF Family Ligands (~24% of pipeline)

1.2 BDNF and TrkB Agonists (~20% of pipeline)

1.3 NGF and TrkA Agonists (~13% of pipeline)

1.4 NT-3 and NT-4 (~5% of pipeline)

2. Insulin-Like Growth Factor (IGF) Family (~11% of pipeline)

3. Fibroblast Growth Factor (FGF) Family (~17% of pipeline)

4. Epidermal Growth Factor (EGF) Family (~5% of pipeline)

5. Ciliary Neurotrophic Factor (CNTF) Family (~7% of pipeline)

6. Other Growth Factor Families (~8% of pipeline)

VEGF (Vascular Endothelial Growth Factor)

PDGF (Platelet-Derived Growth Factor)

TGF-β (Transforming Growth Factor Beta)

Receptor Agonists and Peptide Mimetics

Small Molecule Receptor Agonists

Peptide Mimetics

Engineered Proteins

Gene Therapy Approaches

AAV Vectors in Clinical Development

Manufacturing and Delivery Trends

Non-AAV Approaches

Clinical Trial Landscape

Active Phase 2/3 Trials

Key Historical Trials and Lessons Learned

Clinical Trial Failures: Root Causes

Key Companies and Sponsor Landscape

Major Pharmaceutical Companies

Biotechnology Companies

Academic/Government Programs

Funding Trends

Investment by Growth Factor Family (2020-2025)

Notable Funding Rounds (2023-2025)

Investor Themes

Pipeline Analysis by Indication

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Huntington's Disease

Gap Analysis

Scientific Gaps

Commercial Gaps

Indication Gaps

Strategic Opportunities

Cross-Reference: Related Pages

Gene Pages

Protein Pages

Signaling Pathways

Related Investment Landscapes

Related Therapeutics

See Also

External Links

References

💬 Discussion